The company’s updated guidance for revenue includes approximately $10.5B in anticipated revenues for Comirnaty and Paxlovid, ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the ...

Pfizer reports Q3 EPS of $1.06, surpassing $0.62 consensus, with revenue up 31% to $17.7 billion. Growth driven by Paxlovid, ...

Pfizer (PFE) stock fell even as the company beat forecasts with its Q3 results and increased its full-year outlook.Find out ...

Pfizer (PFE) stock gained after the company beat estimates with its Q3 2024 financials and raised its full-year guidance ...

Pfizer raised its full-year profit forecast after better-than-expected sales of its COVID-19 treatment helped it beat Wall Street estimates for third-quarter earnings on Tuesday.

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock ...

While reporting financial results for the third quarter, drug major Pfizer Inc. (PFE) raised its adjusted earnings and revenue ...

Pfizer PFE reported third-quarter 2024 adjusted earnings per share of $1.06, which crushed the Zacks Consensus Estimate of 64 ...

Pfizer, which is under pressure from activist investor Starboard, on Tuesday topped third-quarter estimates as sales of its COVID-19 treatment Paxlovid blew past Wall Street expectations. The U.S.

Sales of Pfizer’s COVID products, Comirnaty and Paxlovid, are expected to have declined due to lower demand. Pfizer records direct sales and alliance revenues from its partner, BioNTech for the ...

The FDA has amended the emergency use authorisation (EUA) for Comirnaty in line with its experts' advice – for people aged over 65 and other adults at risk of getting severe COVID-19 ...